CBD in cosmetics: what the European threshold of 0.19% means

On 24 April 2026, the European Commission published the final opinion of the Scientific Committee on Consumer Safety on cannabidiol. Two numbers: 0,19% for pure CBD, 0,00025% for THC present as an impurity. After years of regulatory uncertainty, there is now a reference point.

Before celebrating or sounding the alarm, it is worth understanding what was decided, because two things were not decided, and they matter just as much as what was decided. The opinion says that CBD is safe up to 0.19%. It does not say that it works at 0.19%. And it is not a law.

Cover image generated with the support of artificial intelligence.

[INDICE:h2]

CBD beauty arrived first in the imagination

Some ingredients enter cosmetics after years of quiet research. Others arrive first through aesthetics: they become a colour, a ritual, a promise. CBD undoubtedly belongs to the second category.

Between the late 2010s and early 2020s, it appeared in face creams, balms, body oils, and scalp products. The visual language was often the same: sage green, hemp leaves, minimalist formulas, an idea of calm. And sometimes the narrative suggested that the mere presence of cannabidiol was enough to make a product soothing, anti-acne, antioxidant, or even anti-ageing.

This is where the European opinion becomes useful: it neither promotes nor rejects it, but forces us to distinguish between them.

CBD, THC, and hemp oil are not the same thing

Before talking about skin, we need to put the names in order, because much of the confusion starts here.

Cannabidiol (CBD) is one of the compounds in Cannabis sativa and does not produce a psychotropic effect. Delta-9-tetrahydrocannabinol (THC) is the molecule responsible for that effect, and in cosmetics it is discussed only as a residual contaminant in some raw materials.

Then there is hemp seed oil, listed in INCI as Cannabis Sativa Seed Oil. It is a vegetable oil rich in lipids, used as an emollient, and is not equivalent to CBD. A cream with hemp seed oil is not, for that reason alone, a cannabidiol cream. This is one of the most widespread confusions, and sometimes the packaging plays on it.

Finally, there are extracts from different parts of the plant and CBD produced by synthesis. Origin, purity, and composition are not folkloric details: they change the profile of the raw material and its regulatory assessment.

The leaf drawn on the jar tells one story. The INCI tells what was actually formulated. They are two different documents, and only one of them is binding.

Why CBD became a beauty ingredient

The success did not come from nowhere. The skin has an endocannabinoid system: receptors, mediators, and enzymes involved in various skin processes. This foundation fueled scientific interest.

A review published in 2024 in the American Journal of Clinical Dermatology collected the available studies. In laboratory and preclinical models, potentially antioxidant, anti-inflammatory, moisturizing, and sebum-regulating activities emerge. There are also small clinical studies on dermatitis, psoriasis, and scalp irritation.

The same review, however, is clear about the limitations: there are few clinical studies, with small samples, and they use different formulations, concentrations, and conditions. In addition, CBD is a lipophilic molecule, and its distribution in the skin depends greatly on the vehicle. Saying that a product "contains CBD" does not indicate how much reaches where it is supposed to act.

Cannabidiol is therefore not a marketing invention. It is a biologically interesting ingredient with promising signals. It is not a shortcut that allows an in vitro finding to be transferred directly to the cream on the bedside table.

What 0.19% really means

The decisive word in the opinion is safety. The SCCS answered a precise question: what concentration of pure CBD can be considered safe in overall cosmetic exposure.

It did not establish that CBD at 0.19% reduces redness, improves acne, or diminishes wrinkles. Nor did it say that it is useless below that threshold. Safety and efficacy are two separate dossiers, assessed using different methods, by different parties, to answer different questions.

There are also three clarifications that are often lost in the coverage.

1. The threshold concerns pure CBD, assessed in dermal products and products for oral use, individually or in combination.
2. The opinion does not cover products that may expose the lungs through inhalation. This means that sprays, aerosols, powders, and any format that generates inhalable particles are excluded: the 0.19% does not apply to those forms because no data were available.
3. The committee explicitly states a limitation: the data received through the call for data were scarce and came from a limited number of sources. The assessment may be updated if more data are received.

The 0.00025% THC level also needs to be read carefully: it is not an invitation to add it; it is the level considered safe when it appears unintentionally as an impurity in a CBD preparation. Legal compliance also depends on national hemp regulations, which are not uniform across Europe.

“The opinion says that CBD is safe up to 0.19%. It does not say that it works at 0.19%. And it is not a law.”

The point that has received little attention: an opinion is not a law

This is the point that interests me most, and the one that has often disappeared from the headlines.

The SCCS is an advisory scientific committee. It provides the Commission with a technical assessment; it does not issue regulations. At present, there is no provision in the Cosmetics Regulation setting CBD at 0.19%: there is an opinion that the Commission may use to propose a restriction, as it has done in the past for other ingredients. It could adopt it, amend it, or leave it as it is.

Likewise, the CosIng database is informational: finding an INCI name in the database does not mean that every raw material or every use is automatically approved.

In the meantime, the usual rule still applies: every cosmetic product placed on the European market must be safe in its final formulation, undergo a safety assessment, and comply with Regulation (EC) No 1223/2009. The source of the raw material, degree of purity, impurities, intended use, and claims all matter. It is less glamorous than a green leaf, but this is where the real stakes lie.

The claims that still require caution

CBD is associated mainly with four areas: sensitive skin, blemishes, hydration, and skin aging. From an experimental standpoint, there are reasons to continue studying all four.

From a consumer perspective, one more step is needed. A formula may contain CBD along with humectants, emollients, niacinamide, or other well-documented ingredients: the improvement observed could depend on the formula as a whole, rather than on the ingredient featured on the label. This is the same misconception that arises around any trending active ingredient.

Also be careful with a word like “soothing.” It can describe a perceived cosmetic effect, but it must not drift into a therapeutic claim. If a product claims to treat a disease through a pharmacological action, it is no longer a cosmetic: it belongs to another product category, with different rules.

The right question is not “does CBD work?” It is: does this product, at this concentration, in this formula, and with these tests, support the result it promises?

How to read a CBD cosmetic

The INCI, first and foremost. Cannabidiol indicates CBD; Cannabis Sativa Seed Oil indicates hemp seed oil. They can coexist in the same formula, but they are not synonyms and do not do the same thing.

The quality of the information. A serious brand should be able to explain the identity of the raw material, how impurities are controlled, and the evidence supporting its claims. The percentage is not mandatory on the label, but that does not authorize anyone to invent it: transparency can be requested without turning every purchase into an investigation.

The type of promise. “Moisturizes” or “helps reduce the feeling of discomfort” are verifiable cosmetic claims. “Cures eczema” or “treats acne” move the product into medical territory and warrant considerable caution.

The complete formula. Skin never encounters an isolated ingredient: it encounters an emulsion, a texture, a preservative system, and a combination of substances applied with a certain frequency. That is where real tolerability and efficacy are built.

My take

I find it useful when a much-discussed ingredient finally receives clear boundaries. Not because a number solves everything, but because it forces us to separate the appeal of a trend from the work required before a raw material becomes a credible formula.

CBD interests me precisely because of this dual nature: it has a powerful pop-culture history and a scientific basis that deserves further study, but it also brings concrete issues involving purity, stability, delivery, and the language used in claims. It is not in our formulas, and not for ideological reasons: for the same functions (comfort, redness, barrier), I had active ingredients with more solid documentation and a supply chain that was easier to control.

If clinical data became robust one day and the supply chain more transparent, I would evaluate it as I evaluate any other active ingredient: where it comes from, how pure it is, what concentration it has, how it behaves in the formula, and which tests have been conducted on the finished product. Trying is useful, and observing is useful, but personal experience does not replace a controlled trial.

A threshold is a starting point, not a verdict

The European opinion neither promotes nor rejects CBD skincare. It does something more concrete: based on the data currently available, it establishes a safety level for pure CBD and a limit for unintentional traces of THC.

For shoppers, the best news is not that CBD has suddenly become miraculous. It's that the debate is becoming more precise: we now know which question concerns safety, which concerns efficacy, and which concerns regulatory compliance. These are three different questions, and for years they were treated as one.

The most interesting part remains to be built: more robust clinical studies, well-characterized formulas, and claims proportionate to the evidence. Only then will CBD be able to move beyond the green-leaf aesthetic and enter data-driven cosmetics with full credibility.

If you're considering a product and want to understand what it really contains before buying it, at LeLang partner pharmacies and parapharmacies you'll find a pharmacist who knows how to read the label, even when it's not one of our products.